drugset / Trial / NCT03511365

Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

NCT03511365

Phase 1/2 Terminated 6 enrolled Northwell Health
NaSingle-groupOpen-labelBasic science

Summary

Individuals with clinically identified non-alcoholic fatty liver disease will undergo baseline evaluation of IL-17 and other inflammatory markers as well as microbiome determination. The probiotic formulation VSL#3 450 Billion CFU twice daily will be administered for 8 weeks and the determination of Il-17 and microbiome will be repeated. Each subject will serve as his or her own control.

Timeline

Start
2018-05-15
Primary completion
2018-12-14
Completion
2019-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject VSL#3 Other / unclassified 4.5e+11 unknown

Indications